Hamad, Jimer A.

HRN: 21-75-40  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/19/2022
CEFTRIAXONE 1G (VIAL)
12/19/2022
12/25/2022
IV
800mg
Q24h
PCAP C
Waiting Final Action 
12/19/2022
CEFTAZIDIME 1GM (VIAL)
12/19/2022
12/26/2022
IVT
350 Mg
8 Hrs
PCAP D
Waiting Final Action 
12/19/2022
CLINDAMYCIN 150MG/ML, 4ML (AMP)
12/19/2022
12/26/2022
IVT
80 Mg
8 Hrs
PCAP D
Waiting Final Action 
12/20/2022
CLARITHROMYCIN 125MG/5ML, 60ML SUSPENSION (BOT)
12/20/2022
12/27/2022
ORAL
2.5ml
Q12
PCAP D
Waiting Final Action 
12/21/2022
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
12/21/2022
12/27/2022
IV
400mg
Q6Hrs
PCAP-D
Waiting Final Action 
12/21/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
12/21/2022
12/27/2022
IV
120mg
Q24Hrs
PCAP-D
Waiting Final Action 
12/21/2022
OXACILLIN 500MG (VIAL)
12/21/2022
12/27/2022
IV
200
Q6
PCAP D
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: